Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection

Overview

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infects host-cells via ACE2-receptors, which leads to pneumonia (COVID-19) but also can lead to myocarditis (acute myocardial injury) and chronic damage to the cardiovascular system. Therefore, cardiovascular protection may be necessary when treating patients with COVID-19 infection. This may especially be necessary in patients with cardiovascular diseases, risk factors, and co-medication.

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 25, 2026

Interventions

  • Diagnostic Test: Assessment of cardiovascular diseases and cardiovascular risk factors
    • At inclusion, patients will be screened for pre-existing cardiovascular diseases and cardiovascular risk factors, as well as medication.

Clinical Trial Outcome Measures

Primary Measures

  • All-cause mortality
    • Time Frame: During 1 year follow-up
    • mortality of any cause

Secondary Measures

  • 30-day mortality
    • Time Frame: Within 30 days after inclusion
    • mortality of any cause
  • Major adverse cardiovascular events
    • Time Frame: During 1 year follow-up
    • Myocardial infarction, stroke, or CV death

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with suspected SARS-CoV2/Covid-19 infection Exclusion Criteria:

  • Unwillingness to participate

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Essen
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Tienush Rassaf, MD, Principal Investigator, University Hospital Essen, Deparment of Cardiology and Vascular Medicine
  • Overall Contact(s)
    • Matthias Totzeck, MD, +49201723, matthias.totzeck@uk-essen.de

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.